CAR-T cell therapy: potential for paediatric brain tumours-an update.

Alexandra Zehner, Benjamin Draper, Darren Hargrave, Laura K Donovan, John Anderson

Abstract readReview

In one paragraph

Review in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alexandra ZehnerUCL Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID http://orcid.org/0000-0002-7629-7723

Benjamin DraperUCL Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID http://orcid.org/0000-0001-7735-3988

Darren HargraveUCL Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID http://orcid.org/0000-0001-8219-9807

Laura K DonovanUCL Great Ormond Street Institute of Child Health, University College London, London, UK.ORCID http://orcid.org/0000-0001-5557-5539

John AndersonUCL Great Ormond Street Institute of Child Health, University College London, London, UK. j.anderson@ucl.ac.uk.ORCID http://orcid.org/0000-0001-7509-3203

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Central nervous system (CNS) tumours are the deadliest cancer for children and currently present limited treatment options. Chimeric antigen receptor (CAR)-T cell therapies have emerged as an innovative approach supported by encouraging clinical results. Current clinical trials using CAR-T cells in the treatment of paediatric CNS cancers differ in a number of variables, including the CAR-T cell route of delivery, presence of lymphodepletion, identified target antigen, and CAR engineering features. Considering early learnings across these areas is an essential step to developing more effective treatment options, especially given the challenges of immunosuppressive tumour microenvironments, various toxicities, CAR-T cell exhaustion, and tumour antigen heterogeneity. In sum, while there is a need for continued innovation, CAR-T cells represent a promising treatment approach for this devastating category of diseases.

Indexed as

Brain NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAnimalsChildHumansReceptors, Chimeric Antigen

Identifiers

PMID42663750

DOI10.1007/s11060-026-05604-5

PMCPMC13525004

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.